Search

Your search keyword '"Moride, Yola"' showing total 418 results
Start Over Author "Moride, Yola" Publication Year Range Last 50 years
418 results on '"Moride, Yola"'

7. An Interrupted Time Series Analysis of the Impact of the COVID-19 Pandemic on Routine Vaccination Uptake in Kenya.

Author

Ngigi, Michael, Moride, Yola, Castilloux, Anne-Marie, and Clemens, Sue Ann Costa

Subjects
TIME series analysis, HEALTH information systems, RUBELLA vaccines, MOVING average process, VACCINATION coverage
Abstract

A strategic priority of the World Health Organization's Immunization Agenda 2030 is to increase vaccination coverage and equity through reaching "zero-dose" children. Through an ecological study, we sought to quantify the impact of the COVID-19 pandemic on the coverage of the pentavalent and the measles/rubella vaccines in Kenya, without implying causality. The monthly number of doses from January 2017 to August 2022 were obtained from the Kenya Health Information System for the pentavalent and the measles/rubella vaccines. Immediate (step) and long-term (ramp) changes following interruptions occurring during the period from March 2020 to December 2020 were assessed through an interrupted time series analysis using an autoregressive integrated moving average (ARIMA) model, accounting for seasonality. In December 2020, there was an immediate decrease of 8337, 12,212, and 20,848 in the number of doses for the first, second, and third dose of the pentavalent vaccine, respectively (statistically significant for the third dose only). This corresponded to a percentage relative difference of −21.6, −20.1, and −24.5, respectively, for three doses of pentavalent vaccines, while for measles/rubella vaccine it was −27.3 and −33.6, respectively, for the first and second dose. COVID-19 resulted in interruptions affecting routine immunization, but recovery occurred within four months. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Von Willebrand Disease Epidemiology, Burden of Illness and Management: A Systematic Review

Author

Du,Ping, Bergamasco,Aurore, Moride,Yola, Truong Berthoz,Françoise, Özen,Gülden, Tzivelekis,Spiros, Du,Ping, Bergamasco,Aurore, Moride,Yola, Truong Berthoz,Françoise, Özen,Gülden, and Tzivelekis,Spiros

Abstract

Ping Du,1 Aurore Bergamasco,2 Yola Moride,2,3 Françoise Truong Berthoz,4 Gülden Özen,1 Spiros Tzivelekis1 1Takeda Development Center Americas, Inc., Cambridge, MA, USA; 2YOLARX Consultants, Paris, France; 3Rutgers, The State University of New Jersey, New Brunswick, NJ, USA; 4Takeda Pharmaceuticals International AG, Zürich, SwitzerlandCorrespondence: Ping Du, Takeda Development Center Americas, Inc., 40 Landsdowne Street, Cambridge, MA, 02139, USA, Tel +1-717-307-0572, Email ping.du@takeda.comIntroduction: Although hereditary von Willebrand disease (VWD) is the most common bleeding disorder, its epidemiology is not well understood. A systematic review (PROSPERO CRD42020197674/CRD42021244374) on the epidemiology/burden of illness of VWD was conducted to better understand patients’ unmet needs.Methods: Observational studies (published January 1, 2010 to April 14, 2021) were identified in MEDLINE and Embase databases, using free-text keywords and thesaurus terms for VWD and outcomes of interest. Pragmatic web-based searches of the gray literature, including conference abstracts, were performed, and reference lists of retained publications were manually searched for additional sources. Case reports and clinical trials (phase 1– 3) were excluded. Outcomes of interest were incidence, prevalence, mortality, patient characteristics, burden of illness, and therapeutic management/treatments currently used for VWD.Results: Of the 3095 identified sources, 168 were included in this systematic review. Reported VWD prevalence (22 sources) ranged from 108.9 to 2200 per 100,000 in population-based studies and from 0.3 to 16.5 per 100,000 in referral-based studies. Reported times between first symptom onset and diagnosis (two sources; mean 669 days; median 3 years) highlighted gaps in timely VWD diagnosis. Bleeding events reported in 72– 94% of the patients with VWD (all types; 27 sources) were mostly mucocutaneous including epistaxis, menorrhagia, and oral/gum bleeding. Poo

Published
2023

26. Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States

Author

Broome, Catherine M., primary, Barcellini, Wilma, additional, Roeth, Alexander, additional, Karaouni, Alia, additional, Joly, Florence, additional, Yoo, Ronnie, additional, Terlinden, Augustin, additional, Adeyemi, Ayo, additional, Moride, Yola, additional, and Hill, Quentin A., additional

Published
2022
Full Text
View/download PDF

39. Predictors of Pain Reduction Among Fibromyalgia Patients Using Medical Cannabis: A Long‐TermProspective Cohort Study

Author

Sotoodeh, Romina, Waldman, Lilach Eyal, Vigano, Antonio, Moride, Yola, Canac‐Marquis, Michelle, Spilak, Tristan, Gamaoun, Rihab, Kalaba, Maja, Hachem, Yasmina, Beaulieu, Pierre, Desroches, Julie, Ware, Mark A., Perez, Jordi, Shir, Yoram, Fitzcharles, Mary‐Ann, and Martel, Marc O.

Abstract

Many patients with fibromyalgia (FM) report using cannabis as a strategy to improve pain. Given that pain often co‐occurs with symptoms of anxiety and depression (i.e., negative affect) and sleep problems among patients with FM, improvements in these symptoms might indirectly contribute to reductions in pain intensity following cannabis use. The main objective of the study was to examine whether changes in pain intensity following initiation of medical cannabis among patients with FM could be attributed to concurrent changes (i.e., reductions) in negative affect and sleep problems. This was a 12‐month prospective cohort study among patients with FM (n = 323) initiating medical cannabis under the care of physicians. Patients were assessed at baseline, and follow‐up assessment visits occurred every 3 months after initiation of medical cannabis. Patients’ levels of pain intensity, negative affect, and sleep problems were assessed across all visits. Multilevel mediation analyses indicated that reductions in patients’ levels of pain intensity were partly explained by concurrent reductions in sleep problems and negative affect (both P< 0.001). This remained significant even when accounting for patients’ baseline characteristics or changes in medical cannabis directives over time (all P> 0.05). Our findings provide preliminary insight into the potential mechanisms of action underlying pain reductions among patients with FM who are using medical cannabis. Given the high attrition rate (i.e., 75%) observed in the present study at 12 months, our findings cannot be generalized to all patients with FM who are using medical cannabis.

Published
2023
Full Text
View/download PDF

43. Encounter Databases

Author

Gerhard, Tobias, primary, Moride, Yola, additional, Pottegård, Anton, additional, and Pratt, Nicole, additional

Published
2021
Full Text
View/download PDF

48. Global Incidence and Prevalence of Gaucher Disease: A Targeted Literature Review.

Author

Castillon, Genaro, Chang, Shun-Chiao, and Moride, Yola

Subjects
GAUCHER'S disease, DISEASE prevalence, LITERATURE reviews, RARE diseases, CROSS-sectional method
Abstract

Incidence and prevalence estimates for Gaucher disease (GD) are scarce for this rare disease and can be variable within the same region. This review provides a qualitative synthesis of global GD incidence and prevalence estimates, GD1–3 type-specific and overall, published in the last 10 years. A targeted literature search was conducted across multiple databases from January 2011 to September 2020, including web-based sources and congress proceedings to May 2021. Searches yielded 490 publications, with 31 analyzed: 20 cohort studies (15 prospective, 5 retrospective), 6 cross-sectional studies, 5 online reports (most from Europe (n = 11) or North America (n = 11); one multiregional). Across all GD types, incidence estimates ranged 0.45–25.0/100,000 live births (16 studies), lowest for Asia-Pacific. Incidence of GD1: 0.45–22.9/100,000 live births (Europe and North America) and GD3: 1.36/100,000 live births (Asia-Pacific only). GD type-specific prevalence estimates per 100,000 population were GD1: 0.26–0.63; GD2 and GD3: 0.02–0.08 (Europe only); estimates for GD type unspecified or overall ranged 0.11–139.0/100,000 inhabitants (17 studies), highest for North America. Generalizability was assessed as "adequate"or "intermediate" for all regions with data. GD incidence and prevalence estimates for the last 10 years varied considerably between regions and were poorly documented outside Europe and North America. Data for GD2 and GD3 were limited. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results